Computational screening of FDA-approved hepatitis c drugs for inhibition of VEGFR2 in liver cancer
Liver cancer (LC) is one of the most common tumours and the leading cause of cancer-related death globally. Amidst the problems associated with existing treatments, such as hepatotoxicity, recurrence, drug resistance, and other adverse effects, researchers are under pressure to find alternatives. To...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
2024
|
| Subjects: | |
| Online Access: | http://umpir.ump.edu.my/id/eprint/43151/1/Computational%20Screening%20of%20FDA-Approved%20Hepatitis%20C.pdf |